CL2014003535A1 - Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado. - Google Patents

Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado.

Info

Publication number
CL2014003535A1
CL2014003535A1 CL2014003535A CL2014003535A CL2014003535A1 CL 2014003535 A1 CL2014003535 A1 CL 2014003535A1 CL 2014003535 A CL2014003535 A CL 2014003535A CL 2014003535 A CL2014003535 A CL 2014003535A CL 2014003535 A1 CL2014003535 A1 CL 2014003535A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
rheumatoid arthritis
compounds derived
associated pain
treat osteoarthritis
Prior art date
Application number
CL2014003535A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014003535A1 publication Critical patent/CL2014003535A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014003535A 2012-06-29 2014-12-26 Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado. CL2014003535A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2014003535A1 true CL2014003535A1 (es) 2015-05-08

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003535A CL2014003535A1 (es) 2012-06-29 2014-12-26 Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado.

Country Status (42)

Country Link
US (2) US8962659B2 (esLanguage)
EP (1) EP2867207B1 (esLanguage)
JP (1) JP6127136B2 (esLanguage)
KR (1) KR101653476B1 (esLanguage)
CN (1) CN104411684B (esLanguage)
AP (1) AP2014008164A0 (esLanguage)
AR (1) AR091429A1 (esLanguage)
AU (1) AU2013280875B2 (esLanguage)
BR (1) BR112014031616B1 (esLanguage)
CA (1) CA2875569C (esLanguage)
CL (1) CL2014003535A1 (esLanguage)
CO (1) CO7151507A2 (esLanguage)
CR (1) CR20140553A (esLanguage)
CY (1) CY1119425T1 (esLanguage)
DK (1) DK2867207T3 (esLanguage)
DO (1) DOP2014000287A (esLanguage)
EA (1) EA024392B1 (esLanguage)
EC (1) ECSP14033267A (esLanguage)
ES (1) ES2644812T3 (esLanguage)
GT (1) GT201400288A (esLanguage)
HR (1) HRP20171515T1 (esLanguage)
HU (1) HUE034425T2 (esLanguage)
IL (1) IL236219A (esLanguage)
JO (1) JO3296B1 (esLanguage)
LT (1) LT2867207T (esLanguage)
MA (1) MA37686B1 (esLanguage)
ME (1) ME02840B (esLanguage)
MX (1) MX345324B (esLanguage)
MY (1) MY173878A (esLanguage)
NZ (1) NZ701933A (esLanguage)
PE (1) PE20150182A1 (esLanguage)
PH (1) PH12015500009B1 (esLanguage)
PL (1) PL2867207T3 (esLanguage)
PT (1) PT2867207T (esLanguage)
RS (1) RS56452B1 (esLanguage)
SG (1) SG11201408641UA (esLanguage)
SI (1) SI2867207T1 (esLanguage)
TN (1) TN2014000501A1 (esLanguage)
TW (1) TWI599561B (esLanguage)
UA (1) UA114325C2 (esLanguage)
WO (1) WO2014004229A1 (esLanguage)
ZA (1) ZA201408632B (esLanguage)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
KR101807981B1 (ko) 2013-12-17 2017-12-11 일라이 릴리 앤드 캄파니 페녹시에틸 시클릭 아민 유도체 및 ep4 수용체 조절제로서의 그의 활성
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
KR102632028B1 (ko) 2017-05-18 2024-01-31 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 페닐 유도체
ES2995259T3 (en) * 2019-01-22 2025-02-10 Keythera Suzhou Pharmaceuticals Co Ltd Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
MXPA04005555A (es) * 2002-03-18 2005-05-16 Pfizer Prod Inc Procedimientos de tratamiento con agonistas selectivos del receptor ep4.
KR100752891B1 (ko) * 2003-01-10 2007-08-28 에프. 호프만-라 로슈 아게 프로스타글란딘 작용제로서 2-피페리돈 유도체
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
AP2006003785A0 (en) * 2004-05-04 2006-10-31 Pfizer Substituted methylaryl or heteroaryl amide compounds
BRPI0510598A (pt) * 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2009139373A1 (ja) 2008-05-14 2009-11-19 アステラス製薬株式会社 アミド化合物
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
BR112012020236A2 (pt) 2010-02-22 2016-05-17 Raqualia Pharma Inc uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
PE20131343A1 (es) * 2010-09-21 2013-11-18 Eisai Randd Man Co Ltd Derivados de acido benzoico
EP2729445B1 (en) * 2011-07-04 2015-10-21 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor antagonists
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Also Published As

Publication number Publication date
WO2014004229A1 (en) 2014-01-03
NZ701933A (en) 2017-01-27
LT2867207T (lt) 2017-10-10
BR112014031616A2 (pt) 2017-06-27
MX345324B (es) 2017-01-25
EA024392B1 (ru) 2016-09-30
PH12015500009B1 (en) 2020-10-09
PE20150182A1 (es) 2015-02-13
DOP2014000287A (es) 2015-01-31
US9402838B2 (en) 2016-08-02
HUE034425T2 (en) 2018-02-28
EP2867207A1 (en) 2015-05-06
JP2015522018A (ja) 2015-08-03
US20140005226A1 (en) 2014-01-02
IL236219A0 (en) 2015-02-01
TW201412717A (zh) 2014-04-01
TN2014000501A1 (en) 2016-03-30
US8962659B2 (en) 2015-02-24
KR20150013893A (ko) 2015-02-05
CY1119425T1 (el) 2018-03-07
IL236219A (en) 2017-12-31
PL2867207T3 (pl) 2018-01-31
MA37686B1 (fr) 2017-04-28
AU2013280875A1 (en) 2014-12-04
CN104411684B (zh) 2016-08-24
ME02840B (me) 2018-01-20
MA37686A1 (fr) 2016-09-30
MY173878A (en) 2020-02-26
MX2014015953A (es) 2015-07-17
JP6127136B2 (ja) 2017-05-10
SI2867207T1 (sl) 2017-10-30
CR20140553A (es) 2015-02-04
BR112014031616B1 (pt) 2022-06-21
HK1203937A1 (en) 2015-11-06
ES2644812T3 (es) 2017-11-30
JO3296B1 (ar) 2018-09-16
KR101653476B1 (ko) 2016-09-01
AR091429A1 (es) 2015-02-04
UA114325C2 (uk) 2017-05-25
PT2867207T (pt) 2017-11-01
CA2875569C (en) 2016-04-19
CO7151507A2 (es) 2014-12-29
HRP20171515T1 (hr) 2017-11-17
TWI599561B (zh) 2017-09-21
RS56452B1 (sr) 2018-01-31
AP2014008164A0 (en) 2014-12-31
SG11201408641UA (en) 2015-01-29
EA201492255A1 (ru) 2015-03-31
CA2875569A1 (en) 2014-01-03
PH12015500009A1 (en) 2015-03-02
EP2867207B1 (en) 2017-08-09
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
US20150126555A1 (en) 2015-05-07
AU2013280875B2 (en) 2015-09-24
DK2867207T3 (en) 2017-09-11
GT201400288A (es) 2015-08-27
ZA201408632B (en) 2017-06-28

Similar Documents

Publication Publication Date Title
CL2014003535A1 (es) Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado.
IL281211A (en) Oligonucleotides for inducing paternal ube3a expression
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
CL2015000256A1 (es) Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BR112016011065A2 (pt) Composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112014032285A2 (pt) materiais ajustáveis
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
CL2015000946A1 (es) Compuestos derivados de quinolinilo unidos a fenilo; composicion farmaceutica y su proceso de elaboracion; un metodo para tratar o mejorar un sindrome trastorno, o enfermedad inflamatoria mediada por ror-gamma-t, tal como artritis reumatoide, psoriasis, enfermedad de crohn, entre otras.
DK2741763T3 (da) Sammensætning til kontrolleret ovariestimulering.
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
DK2897594T3 (da) Farmaceutisk sammensætning
BR112015008113A2 (pt) novo processo para preparar compostos para uso no tratamento de câncer.
CL2015001613A1 (es) Electrodos impregnados para desionización capacitiva, proceso para su preparación y aparato para emplear dichos electrodos.
SMT201500214B (it) Nuova composizione farmaceutica per il trattamentodi infezioni fungine
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
BR112015010271A2 (pt) produto de comicronização, composição farmacêutica e seus usos